Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Three Formulations of Decitabine/Tetrahydrouridine in Healthy Adults
NCT03828084Phase 1Completed
- Sponsor
- EpiDestiny
- Start
- Apr 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of decitabine and tetrahydrouridine in sickle cell disease (SCD), beta thalassemia and myelodysplastic syndrome (MDS) (4 arms), sponsored by EpiDestiny. Primary endpoints: Pharmacokinetics of Decitabine at 24 hours, Decitabine plasma concentration at 24 hours and 1 more. Started Apr 2019; status: completed.
02
Drugs
decitabinetetrahydrouridine
03
Conditions
sickle cell disease (SCD)beta thalassemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03828084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03828084.